SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

MORARI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.123
AS - Asia 5.205
EU - Europa 3.470
SA - Sud America 765
AF - Africa 77
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 21.654
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.876
SG - Singapore 2.125
CN - Cina 1.617
DE - Germania 776
BR - Brasile 657
UA - Ucraina 619
IT - Italia 517
HK - Hong Kong 458
GB - Regno Unito 412
TR - Turchia 407
FI - Finlandia 343
VN - Vietnam 238
SE - Svezia 176
RU - Federazione Russa 149
CA - Canada 121
PL - Polonia 111
MX - Messico 104
FR - Francia 96
ID - Indonesia 89
IN - India 80
AT - Austria 61
AR - Argentina 51
BE - Belgio 51
JP - Giappone 48
ZA - Sudafrica 43
NL - Olanda 39
ES - Italia 38
BD - Bangladesh 36
LT - Lituania 26
IQ - Iraq 18
EC - Ecuador 14
CO - Colombia 13
PK - Pakistan 13
EG - Egitto 12
PE - Perù 12
IR - Iran 11
CZ - Repubblica Ceca 9
NO - Norvegia 9
AU - Australia 8
BG - Bulgaria 8
MA - Marocco 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 6
IE - Irlanda 6
IL - Israele 6
UZ - Uzbekistan 6
CL - Cile 5
JO - Giordania 5
KE - Kenya 5
PY - Paraguay 5
VE - Venezuela 5
AZ - Azerbaigian 4
CH - Svizzera 4
KG - Kirghizistan 4
NP - Nepal 4
PH - Filippine 4
RO - Romania 4
AL - Albania 3
CR - Costa Rica 3
DK - Danimarca 3
DZ - Algeria 3
ET - Etiopia 3
HN - Honduras 3
JM - Giamaica 3
KZ - Kazakistan 3
LV - Lettonia 3
PA - Panama 3
TT - Trinidad e Tobago 3
BH - Bahrain 2
DM - Dominica 2
DO - Repubblica Dominicana 2
EE - Estonia 2
EU - Europa 2
HR - Croazia 2
KH - Cambogia 2
KR - Corea 2
NZ - Nuova Zelanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
CG - Congo 1
GE - Georgia 1
GH - Ghana 1
GT - Guatemala 1
KY - Cayman, isole 1
LK - Sri Lanka 1
NI - Nicaragua 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
TW - Taiwan 1
Totale 21.652
Salva come PNG Salva come JPEG
Città #
Ashburn 1.373
Fairfield 1.266
Singapore 1.245
Woodbridge 1.234
Houston 700
Jacksonville 672
Chandler 666
Beijing 632
Santa Clara 577
Ann Arbor 517
Seattle 482
Hong Kong 455
Wilmington 450
Cambridge 415
Munich 365
Dallas 264
Izmir 237
Los Angeles 177
Nanjing 173
Ferrara 167
Princeton 165
New York 159
Helsinki 142
San Diego 114
Boardman 105
Warsaw 102
Shanghai 100
Milan 90
Ho Chi Minh City 80
Jakarta 70
Bremen 66
Mexico City 62
São Paulo 61
Turku 58
Shenyang 57
London 56
Hanoi 51
Brussels 50
Falls Church 48
Brooklyn 46
Hebei 45
Hefei 45
Tianjin 44
Tokyo 44
Vienna 44
Moscow 43
The Dalles 43
Buffalo 41
Chicago 40
Montreal 40
Atlanta 38
Nanchang 38
Frankfurt am Main 37
Boston 35
Denver 32
Changsha 31
Toronto 31
Jiaxing 29
Norwalk 29
Orem 29
Stockholm 29
Chennai 27
Johannesburg 26
Poplar 26
San Mateo 25
Washington 25
Auburn Hills 24
San Francisco 24
Ankara 23
Jinan 22
Rio de Janeiro 22
Mountain View 21
Falkenstein 20
Redwood City 20
Phoenix 19
Manchester 18
Dearborn 17
Rome 17
Zhengzhou 17
Brasília 15
Charlotte 15
Guangzhou 15
Ottawa 15
Querétaro 15
Council Bluffs 14
Orange 14
Amsterdam 13
Belo Horizonte 13
Biên Hòa 13
Leawood 13
Mcallen 13
New Delhi 13
Secaucus 13
Lappeenranta 12
Montréal 12
Nuremberg 12
Roubaix 12
Addison 11
Augusta 11
Columbus 11
Totale 15.204
Salva come PNG Salva come JPEG
Nome #
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 341
Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111 332
Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity 277
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain 237
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 233
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists 224
GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats 220
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice 220
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia 218
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 208
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 203
Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia 199
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels 198
5‐Hydroxytryptamine‐mediated effects of nicotine on endogenous GABA efflux from guinea‐pig cortical slices 197
AMPA receptor activation regulates the glutamate metabotropic receptor stimulated phosphatidylinositol turnover in human cerebral cortex slices 197
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G i/o protein linked pathways 195
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease 190
Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease 188
Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: Involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity 188
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 187
Loss of cortical GABA terminals in Unverricht–Lundborg disease 187
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels 181
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain 179
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: In vitro studies 179
Striatal Dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors 177
Changes of glutamatergic control of striatal acetylcholine release in experimental parkinsonism 177
Differential responsiveness of rat striatal nerve endings to the mitochondrial toxin 3-nitropropionic acid: implications for Huntington’s disease 177
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging 176
NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid 175
Role of LRRK2 in the regulation of dopamine receptor trafficking 174
Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine 173
Genetic deletion of Rhes or pharmacological blockade of mTORC1 prevent striato-nigral neurons activation in levodopa-induced dyskinesia 173
Antagonisti dei recettori NOP e loro usi terapeutici 172
Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism 172
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex 171
Effect of acute and subchronic nicotine treatment on cortical efflux of [3H]‐d‐aspartate and endogenous GABA in freely moving guinea‐pigs 171
Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release 170
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors 169
Alpha-2 adrenoreceptor-mediated decrease in gamma-aminobutyric acid outflow in cortical slices and synaptosomes during morphine tolerance 169
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 169
Autophagy and LRRK2 in the Aging Brain 169
Loss of the preferential control over the striato-nigral direct pathway by striatal NMDA receptors in a rat model of Parkinson's disease 169
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway 168
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes 168
Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands 167
G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice 164
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity 164
Lipid nanocarriers containing a Levodopa prodrug with potential antiparkinsonian activity 164
NOP receptor ligands and Parkinson’s disease 163
Progressive Motor Cortex Functional Reorganization Following 6-Hydroxydopamine Lesioning in Rats 162
NMDA and non-NMDA ionotropic glutamate receptors modulate striatal acetylcholine release via pre- and postsynaptic mechanisms 161
Glutamate antagonists prevent morphine withdrawal in mice and guinea pigs 161
Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study 160
Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease 160
Nociceptin/Orphanin FQ Receptor Agonists Attenuate L-DOPA-Induced Dyskinesias 158
Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats 157
Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism 157
Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release 155
Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors 153
Differential role of striatal and nigral D1receptors in the expression of L-DOPA induced dyskinesia and its neurochemical correlates 153
Nanostructured lipid carriers as delivery systems for parkinson’s therapy 152
Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4 151
Excitatory amino acids (EAAs) stimulate phosphatidylinositol turnover in adult rat striatal slices: interaction between NMDA and EAA metabotropic receptors. 148
Agonisti dei recettori NOP per il trattamento delle discinesie da levodopa; 147
Effect of (-)nicotine on GABA efflux from guinea pig cerebral cortex slices. 147
Stimulation of Delta Opioid Receptor and Blockade of Nociceptin/Orphanin FQ Receptor Synergistically Attenuate Parkinsonism 147
Inhibitory effect of NMDA receptor activation on quisqualate-stimulated phosphatidylinositol turnover in the human cerebral cortex 145
Parkinson's disease: no NOP, new hope 144
Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro 144
Functional neuroanatomy of the nigrostriatal and striatonigral pathways as studied with dual probe microdialysis in the awake rat - I. Effects of perfusion with tetrodotoxin and low-calcium medium 142
Evidence for a striatal NMDA receptor modulation of nigral glutamate release. A dual probe microdialysis study in the awake freely moving rat 141
Presynaptic group I and II metabotropic glutamate receptors oppositely modulate striatal acetylcholine release 140
Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease 137
Nociceptin/orphanin FQ and neurotransmitter release in the central nervous system 134
Mitochondrial P2X7 Receptor Localization Modulates Energy Metabolism Enhancing Physical Performance 134
Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat 133
Nociceptin/orphanin FQ receptor antagonists riverse akinesia in rat parkinsonian models 132
Nociceptin/orphanin FQ receptors modulate locomotion and motor cortex excitability in adult Rats 132
Managing Parkinson's disease: moving ON with NOP 132
Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis 131
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum 128
Metabotropic glutamate 2 receptors modulate synaptic inputs and calcium signals in striatal cholinergic interneurons 128
Novel therapeutic strategies for treatment of motor abnormalities in Parkinson’s disease: focus on opioid receptors 127
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling 126
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease 125
L-DOPA-induced modulation of GABA and glutamate release in the substantia nigra pars reticulata and globus pallidus in a rat model of dyskinesia 124
Synthesis and structure activity relationships of delthorphine analogues 121
Nociceptin/orphanin FQ receptor antagonists as a novel therapeutic approach to Parkinson’s disease: interaction with levodopa 121
Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin 118
Physiopathological aspects of NMDA transmission in the basal ganglia. In vitro and in vivo release studies 116
Differential regulation of striato-nigral and striato-pallidal pathways by striatal NR2A and NR2B subunit containing receptors 116
Nociceptin/orphanin FQ modulates neurotransmitter release in the substantia nigra: Biochemical and behavioural outcome 116
NR2A and NR2B Subunit Selective NMDA antagonists improve motor performance and reduce pallidal GABA release in 6-OHDA hemilesioned rats 116
L-glutamate and gamma-aminobutyric acid efflux from rat cerebrocortical synaptosomes: Modulation by kappa- and mu- but not delta- and opioid receptor like-1 receptors 116
Nociceptin/orphanin FQ receptor antagonists reverse parkinsonism in MPTP-treated mice and non-human primates 114
The selective D3 receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats 114
PRIN 2008. ente finanziatore MIUR. titolo"Nuovi approcci terapeutici per le discinesie indotte dal trattamento con L-DOPA in un modello sperimentale di Parkinson: ruolo delle subunità del recettore NMDA e della via molecolare Ras-ERK" 114
null 113
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives 110
null 108
Totale 16.360
Salva come PNG Salva come JPEG
Categoria #
all - tutte 105.053
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.199
Totale 107.252
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.239 0 0 0 0 0 166 104 237 67 262 264 139
2021/20221.562 53 169 130 70 81 95 98 87 55 117 153 454
2022/20231.619 170 132 75 181 263 218 72 124 224 4 101 55
2023/2024803 84 103 39 23 76 135 34 63 24 19 9 194
2024/20253.708 74 88 310 82 402 505 146 204 569 373 528 427
2025/20265.619 1.178 343 893 1.354 1.681 170 0 0 0 0 0 0
Totale 21.871